Baseline characteristics

Chemotherapy Followed by Allogeneic Stem Cell Transplantation for Hematologic Malignancies · Source last updated 2020-11-23

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms

1. counts

   1. group Id

      BG000

      value

      18

   units

   Participants

groups

1. description

   Chemo, stem cell transplantation, HLA-Matched related allogeneic stem cell transplantation, leukapheresis, G-CSF, peripheral blood stem cell transplant, fludarabine, cyclophosphamide, donor lymphocyte infusion, cyclosporine, methotrexate Stem Cell Transplant: Donor: Prior to mobilization, leukapheresis to collect CD3+ cells. The donor will then receive G-CSF (10 mcg/kg/day) with leukapheresis collection of peripheral blood stem cells on days 5, 6 and 7 as needed. Goal of leukapheresis will be \> 5 x 106 CD34+cells/kg of recipient. Patient: Peripheral Blood Stem Cell (PBSC) Transplant. Fludarabine 25mg/m2/d IV over 30 minutes on days -6 to -2, followed by cyclophosphamide 1g/m2/d IV on days -3 and -2. This will be followed by allogeneic stem cell infusion 48 hours later. Donor Lymphocyte Infusion (DLI) and Adjustment of Immunosuppression: Cyclosporine (CSA) and methotrexate (MTX) will be used for GvHD prophylaxis with target CSA levels of 200-400 ng/ml. G-CSF: 10 mcg/k

   id

   BG000

   title

   Study Treatment

measures

1. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            value

            0

         title

         <=18 years

      2. measurements

         1. group Id

            BG000

            value

            18

         title

         Between 18 and 65 years

      3. measurements

         1. group Id

            BG000

            value

            0

         title

         >=65 years

      denoms

      1. counts

         1. group Id

            BG000

            value

            18

         units

         Participants

   param Type

   COUNT_OF_PARTICIPANTS

   title

   Age, Categorical

   unit Of Measure

   Participants

2. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            lower Limit

            38

            upper Limit

            65

            value

            57

      denoms

      1. counts

         1. group Id

            BG000

            value

            18

         units

         Participants

   dispersion Type

   FULL_RANGE

   param Type

   MEDIAN

   title

   Age, Continuous

   unit Of Measure

   years

3. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            value

            12

         title

         Female

      2. measurements

         1. group Id

            BG000

            value

            6

         title

         Male

      denoms

      1. counts

         1. group Id

            BG000

            value

            18

         units

         Participants

   param Type

   COUNT_OF_PARTICIPANTS

   title

   Sex: Female, Male

   unit Of Measure

   Participants

4. classes

   1. denoms

      1. counts

         1. group Id

            BG000

            value

            0

         units

         Participants

   param Type

   COUNT_OF_PARTICIPANTS

   population Description

   Race and Ethnicity were not collected from any participant.

   title

   Race and Ethnicity Not Collected

   unit Of Measure

   Participants

5. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            value

            18

      denoms

      1. counts

         1. group Id

            BG000

            value

            18

         units

         Participants

      title

      United States

   param Type

   NUMBER

   title

   Region of Enrollment

   unit Of Measure

   participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice